Related Experiment Video

Updated: Jun 21, 2026

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

Treatment of HER2-positive metastatic breast cancer following initial progression

Ingrid A Mayer1

  • 1Department of Medicine and Breast Cancer Research Program, Vanderbilt-Ingram Comprehensive Cancer Center, Vanderbilt University School of Medicine, Nashville, TN 37232, USA. ingrid.mayer@vanderbilt.edu

Clinical Breast Cancer
|July 15, 2009
PubMed

Insights

Trastuzumab resistance is a growing challenge in HER2-overexpressing metastatic breast cancer. Understanding resistance mechanisms and novel agents is crucial for optimizing anti-HER2 therapy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Molecular-targeted therapies have improved treatment for HER2-overexpressing metastatic breast cancer.
  • Trastuzumab, an anti-HER2 monoclonal antibody, shows significant activity but can encounter de novo and acquired resistance.
  • The increasing use of trastuzumab in both metastatic and adjuvant settings highlights the clinical importance of addressing resistance.

Purpose of the Study:

  • To review key considerations for anti-HER2 treatment decisions in the metastatic setting.
  • To discuss the benefit of continuing trastuzumab after progression on first-line therapy.
  • To explore novel anti-HER2 agents and molecular mechanisms of trastuzumab resistance.

Main Methods:

  • Literature review of randomized trials and recent studies on HER2-overexpressing metastatic breast cancer.
  • Analysis of clinical decision-making points for anti-HER2 therapies.
  • Examination of molecular mechanisms underlying trastuzumab resistance.

Main Results:

  • Trastuzumab resistance is a significant clinical challenge in HER2-overexpressing metastatic breast cancer.
  • Novel anti-HER2 agents offer new treatment options.
  • Understanding resistance mechanisms is key to developing improved therapeutic strategies.

Conclusions:

  • Optimizing anti-HER2 therapy requires careful consideration of treatment continuation, novel agents, and resistance mechanisms.
  • Identifying novel therapeutic targets is essential for enhancing response duration and magnitude.
  • Further research into trastuzumab resistance mechanisms will guide future treatment advancements.

More Related Videos

Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells10:01

Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells

Published on: August 2, 2022

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.